State-Of-The-Art Human Gene Therapy: Part II. Gene Therapy Strategies and Clinical Applications

被引:0
|
作者
Wang, Dan [1 ]
Gao, Guangping [1 ,2 ,3 ]
机构
[1] Univ Massachusetts, Sch Med, Gene Therapy Ctr, Worcester, MA 01605 USA
[2] Univ Massachusetts, Sch Med, Dept Microbiol & Physiol Syst, Worcester, MA 01605 USA
[3] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610064, Sichuan, Peoples R China
基金
美国国家卫生研究院;
关键词
LEBER CONGENITAL AMAUROSIS; ENGINEERED NUCLEASES; IMMUNE-RESPONSES; RPE65; MUTATIONS; VECTORS; PROGRESS; AUGMENTATION; CONSTRUCTS; PROTECTION; INFECTION;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
In Part I of this Review (Wang and Gao, 2014), we introduced recent advances in gene delivery technologies and explained how they have powered some of the current human gene therapy applications. In Part II, we expand the discussion on gene therapy applications, focusing on some of the most exciting clinical uses. To help readers to grasp the essence and to better organize the diverse applications, we categorize them under four gene therapy strategies: (1) gene replacement therapy for monogenic diseases, (2) gene addition for complex disorders and infectious diseases, (3) gene expression alteration targeting RNA, and (4) gene editing to introduce targeted changes in host genome. Human gene therapy started with the simple idea that replacing a faulty gene with a functional copy can cure a disease. It has been a long and bumpy road to finally translate this seemingly straightforward concept into reality. As many disease mechanisms unraveled, gene therapists have employed a gene addition strategy backed by a deep knowledge of what goes wrong in diseases and how to harness host cellular machinery to battle against diseases. Breakthroughs in other biotechnologies, such as RNA interference and genome editing by chimeric nucleases, have the potential to be integrated into gene therapy. Although clinical trials utilizing these new technologies are currently sparse, these innovations are expected to greatly broaden the scope of gene therapy in the near future.
引用
收藏
页码:151 / 161
页数:11
相关论文
共 50 条
  • [31] Clinical applications of retinal gene therapy
    Lipinski, Daniel M.
    Thake, Miriam
    MacLaren, Robert E.
    PROGRESS IN RETINAL AND EYE RESEARCH, 2013, 32 : 22 - 47
  • [32] Clinical applications of vascular gene therapy
    Rutanen J.
    Rissanen T.T.
    Kivelä A.
    Vajanto I.
    Ylä-Herttuala S.
    Current Cardiology Reports, 2001, 3 (1) : 29 - 36
  • [33] Gene Therapy for Neuroprotection and Neurorestoration (Part II)
    Ashraf, Ghulam Md
    Uddin, Md Sahab
    CURRENT GENE THERAPY, 2020, 20 (03) : 163 - 163
  • [34] WFH State-of-the-art paper 2020: In vivo lentiviral vector gene therapy for haemophilia
    Cantore, Alessio
    Naldini, Luigi
    HAEMOPHILIA, 2021, 27 : 122 - 125
  • [35] Herpesvirus gene vectors and applications to human gene therapy
    J.C.Gloriosc
    D.J.Fink
    实验血液学杂志, 1997, (03) : 283 - 283
  • [36] PHOTODYNAMIC THERAPY - THE STATE-OF-THE-ART
    CARRUTH, JAS
    LASERS IN SURGERY AND MEDICINE, 1986, 6 (04) : 404 - 407
  • [37] STATE-OF-THE-ART THERAPY OF CHD
    不详
    UNION MEDICALE DU CANADA, 1991, 120 (03): : 238 - 238
  • [38] Gene therapy in cardiovascular disease - State of the art
    White, DC
    Milano, CA
    ANNALS OF SURGERY, 2003, 238 (06) : S90 - S97
  • [39] Gene Therapy for Neuronopathic Mucopolysaccharidoses: State of the Art
    de Castro, Maria Jose
    del Toro, Mireia
    Giugliani, Roberto
    Couce, Maria Luz
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (17)
  • [40] Cancer gene therapy:: Strategies and clinical trials
    Prados, J
    Melguizo, C
    Boulaiz, H
    Marchal, JA
    Aránega, A
    CELLULAR AND MOLECULAR BIOLOGY, 2005, 51 (01) : 23 - 36